Dabrafenib, also known as GSK2118436 , is an orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity. Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. B-raf belongs to the the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which may be constitutively activated due to BRAF gene mutations. On May 29, 2013, FDA approved this drug.
Rheault, Tara R.; Stellwagen, John C.; Adjabeng, George M.; Hornberger, Keith R.; Petrov, Kimberly G.; Waterson, Alex G.; Dickerson, Scott H.; Mook, Robert A.; Laquerre, Sylvie G.; King, Alastair J.; Rossanese, Olivia W.; Arnone, Marc R.; Smitheman, Kimberly N.; Kane-Carson, Laurie S.; Han, Chao; Moorthy, Ganesh S.; Moss, Katherine G.; Uehling, David E. Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven Tumors. ACS Medicinal Chemistry Letters. Volume 4. Issue 3. Pages 358-362. Journal; Online Computer File. (2013).
Kim, Taehoon; McCarver, Stefan J.; Lee, Chulbom; MacMillan, David W. C. Sulfonamidation of Aryl and Heteroaryl Halides through Photosensitized Nickel Catalysis. Angewandte Chemie, International Edition. Volume 57. Issue 13. Pages 3488-3492. Journal; Online Computer File. (2018).
Ren, Wei. Method for preparing new melanoma drug dabrafenib. CN 107987071. (2018).
Xu, Xuenong. Process for preparation of Dabrafenib via sulfonamidation, halogenation, thiazole cyclization, acetylation, and pyrimidine cyclization. Assignee Suzhou Miracpharma Technology Co., Ltd., Peop. Rep. China. CN 103588767. (2018).
Adams, Jerry Leroy; Dickerson, Scott Howard; Johnson, Neil W.; Kuntz, Kevin; Petrov, Kimberly; Ralph, Jeffrey M.; Rheault, Tara Renae; Schaaf, Gregory; Stellwagen, John; Tian, Xinrong; Uehling, David Edward; Waterson, Alex Gregory; Wilson, Brian. Preparation of benzenesulfonamidethiazole derivatives and analogs for use as B-Raf protein kinase inhibitors. Assignee SmithKline Beecham Corporation, USA. WO 2009137391. (2009).
